Third-quarter jump for PharmAthene

Annapolis - PharmAthene, an Annapolis-based biodefense firm, announced earlier this month that its revenue jumped to $10.7 million in the third quarter compared with $3.4 million for the same quarter last year.

Company officials attributed the increase to U.S. government contracts for the development of its Protexia, SparVax and RyVax vaccines. PharmAthene also bought the rights to develop the anthrax vaccines of Avecia in the second quarter, according to company officials.

PharmAthene now is bidding on a contract from the U.S. Department of Health and Human Services that calls for 25...